Drugs / Corneal Endothelial Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06630169 | Sep 2024 → Oct 2025 overdue | corneal edema | Aurion Biotech | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Results Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗
In this Phase 1/2 double-masked, parallel-arm, dose-ranging study ( NCT06041256 ), patients treated with a single dose of AURN001 corneal endothelial cell (CEC) therapy demonstrated a clear dose-dependent response, with the greatest efficacy observed in the high-dose group. |
| 2024-09-15 | Aurion Biotech | Regulatory Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea aurionbiotech.com ↗
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced the commercial launch of Vyznova® (generic name: neltependocel ) in Japan, for the treatment of bullous keratopathy of the cornea. |
| 2023-03-22 | Aurion Biotech | Regulatory Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application aurionbiotech.com ↗
The Company believes this is the first-ever regulatory approval in the world for an allogeneic cell therapy to treat corneal endothelial disease. |
| 2021-07-25 | Aurion Biotech | Results Aurion Biotech Announces IOTA Cell Therapy Trial aurionbiotech.com ↗
The initial readout from this proof-of-concept trial is promising: patients have demonstrated improvements in visual acuity and central corneal thickness. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-10-18 | Aurion Biotech | Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months aurionbiotech.com ↗ |
| 2024-09-15 | Aurion Biotech | Aurion Biotech Launches Vyznova® in Japan for the Treatment of Bullous Keratopathy of the Cornea aurionbiotech.com ↗ |
| 2023-03-22 | Aurion Biotech | Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application aurionbiotech.com ↗ |
| 2021-07-25 | Aurion Biotech | Aurion Biotech Announces IOTA Cell Therapy Trial aurionbiotech.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Corneal Endothelial Cells | “Corneal Endothelial Cells and Y27632” NCT06630169 ↗ |